Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Rocket Lab enters the first full week of October with a notable change in character: the stock is up 7.7% on the week to $75.06, short interest has quietly rebuilt, and a fresh Citigroup initiation has added institutional weight to an already bullish analyst consensus.
The reversal from last week's note is worth naming clearly. Seven days ago, shorts were covering and the stock was down 3.2%. This week, both dynamics flipped. Short interest has edged back up 1.4% over the past week to 46.7 million shares, representing 8.75% of the free float, reversing the covering trend noted at end of September. The month-on-month climb of 9% shows shorts have been rebuilding positions since late August, even as the stock rerated higher. The lending market remains uncrowded. Availability is 263%, meaning nearly three shares are available to borrow for every one currently out on loan, tight relative to the 52-week loosest reading near 360% but well above any squeeze territory. Cost to borrow has also drifted higher, up 17.5% on the week to 0.46%, though in absolute terms it remains low. The options market adds a mild defensive tilt: the put/call ratio at 0.74 is modestly above its 20-day average of 0.72, with a z-score of 1.22, not alarming but suggesting marginally more hedging activity than usual as the stock approaches its November 10 earnings date. Together, the picture is one of tentative short-side rebuilding against a stock that is still moving up.
The Street is broadly bullish, and recent coverage additions have reinforced that. Citigroup initiated with a Buy and a $105 target on October 1, the most recent and highest-profile addition to a consensus that now counts 13 buy ratings. Raymond James initiated at Outperform in September with an $80 target, while Bank of America maintained Buy after trimming its target to $110 from $115 post-Q2 results. Cantor Fitzgerald lifted its target to $122 after the August print. The mean price target of $109.15 implies around 45% upside from current levels. Bulls point to a $2.36 billion backlog, $800 million in bookings added after quarter-end, and Neutron final assembly underway. Bears focus on the path to profitability: Q2 revenue of $234.1 million came with a $49.3 million net loss, and Q3 gross margin guidance of 29% to 31% is a step back from Q2's 36.1%. The factor score picture reflects the tension: EPS momentum over 30 days ranks in the 100th percentile, while the 90-day reading drops to the 1st, a sign that near-term estimate revisions are running ahead of any durable earnings trend. The short score of 54.7 is mid-range and has barely moved in two weeks, consistent with positioning that is not at an extreme in either direction.
Insider activity is worth flagging, though the signal is structured rather than discretionary. CFO Adam Spice exercised options and sold shares totalling just over $9.9 million on October 1, all under a pre-arranged 10b5-1 plan. A similar round of plan-driven sales occurred on September 2. The 90-day net insider position is minus 3.7 million shares with a net value of roughly minus $313 million, a large figure in dollar terms but almost entirely composed of these scheduled transactions. The same plan mechanics apply to a $1 million sale by COO Frank Klein in late August. Planned sales are compensation mechanics, not expressions of negative conviction, and should be read that way.
On the 13D register, CEO Peter Beck remains a disclosed activist filer after reducing from 10% to 7.51% of the class, last filed in March. VK Services, linked to venture capital, has trimmed from 9% to 6.5% across several filings since late 2025. BlackRock added 2.6 million shares in a recent filing to reach 6.78% of shares. These are significant holders, and their directional changes are worth monitoring, but the activist caveat applies: 13D/G stakes are event-driven disclosures and positions can move materially below the 5% threshold without a further filing.
The next print is November 10, 34 days away. The last two earnings reactions were a 10.7% rally on the May report and a 3.4% fall on the August report, so the stock has shown it can move sharply in either direction. With short interest now edging back up, availability moderately tightened from late-September levels, and analysts clustered well above current price, the setup into that date is the more interesting question than this week's rally.
See the live data behind this article on ORTEX.
Open RKLB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
